[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intravenous\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intravenous":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,77,99,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100632269","ondansetron-lozenge-versus-intravenous-for-prevention-of-shivering-in-cesarean-section-100632269",false,"NCT07511491","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 40 years.\n* American Society of Anesthesiology (ASA) physical status II.\n* Parturient women undergoing cesarean section under spinal anesthesia.\n\nExclusion Criteria:\n\n* Parturient women with any contraindication or hypersensitivity to the study drugs.\n* Any history of cardiovascular diseases, psychosis, hypertension, fetal distress, cord prolapse initial.\n* Preoperative shivering.\n* Preoperative fever (\\>38°C).\n* Body mass index \\> 40 kg\u002Fm2.\n* Medical history of alcohol or drug abuse.\n* Hypo- or hyperthyroidism.\n* Parkinson's disease or any extrapyramidal disease.\n* Intraoperative blood transfusion.","FEMALE","18 Years","40 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).",[27,28,29,30,31,32],"Ondansetron","Lozenge","Intravenous","Prevention","Shivering","Cesarean Section","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-23","ACTUAL",{"date":39,"type":37},"2026-04-11",{"date":41,"type":21},"2026-08-30",{"name":43,"class":44},"Tanta University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100640645","phase-2-multicenter-phase-ii-trial-of-nricm102-combined-with-standard-therapy-in-pneumonia-100640645","NCT07583992","Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia","Inclusion Criteria:\n\n1. Male or female subjects aged 18 to 85 years\n2. The subjects are diagnosed with community-acquired pneumonia (CAP) at the time of hospital admission and must meet all of the following criteria:\n\n   Chest X-ray showing new onset or persistent pulmonary infiltrate At least two of the following abnormal clinical or laboratory findings: (a) Cough, (b) Sputum production, (c) Fever (≥37.8℃) or hypothermia (\\\u003C35℃), (d) Auscultatory findings of rales or bronchial breath sounds, (e) White blood cell count greater than 10×10⁹\u002FL or less than 4×10⁹\u002FL\n3. Subjects requiring hospitalization and intravenous antibiotic therapy\n4. Subjects who have received standard antibiotic therapy for less than 24 hours after hospital admission\n5. Subjects who are able to take the investigational product orally\n6. Subjects who are able to understand and comply with all study procedures and provide written informed consent\n\nExclusion Criteria:\n\n1. Subjects who have received systemic antibiotic treatment within 72 hours prior to screening; routine antibiotics administered after hospital admission are not included in this restriction\n2. Subjects who have used oral traditional Chinese medicine (TCM) or traditional Chinese medicine preparations that may affect efficacy assessment within 7 days prior to hospital admission\n3. Subjects who have been hospitalized within 15 days prior to current admission\n4. Subjects with aspiration pneumonia\n5. Subjects requiring admission to the intensive care unit (ICU)\n6. Subjects requiring hemodialysis\n7. Subjects with any malignancy, except those who have completed curative treatment with no signs of recurrence for more than five years and require no further anticancer therapy (based on medical history)\n8. Subjects with human immunodeficiency virus (HIV) infection\n9. Subjects requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), steroids, or other immunosuppressants\n10. Subjects requiring antiviral agents for COVID-19 infection or influenza\n11. Subjects must be on a stable dose of Omeprazole or Warfarin\n12. Subjects with alcohol or substance abuse, or other major organic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, tuberculosis (TB), or significant heart, kidney, or other major organ dysfunction or failure (based on medical history)\n13. Female subjects who are pregnant, breastfeeding, or of childbearing potential, or those intending to become pregnant between the signing of the Informed Consent Form (ICF) and the final observation\u002Fstudy time point, or who are unwilling to use an appropriate method of contraception. Acceptable highly effective methods of contraception include:\n\n    1. Surgical sterilization (male or female), contraceptive implants, or intrauterine devices (IUDs).\n    2. Injectable contraceptives, oral contraceptives, contraceptive patches, or vaginal rings, used in combination with one barrier method.\\*\n    3. Combination of two barrier methods.\\* \\*Effective barrier methods include diaphragms, male or female condoms, contraceptive sponges, or spermicides (creams or gels containing spermicidal chemicals).\n14. Subjects deemed unsuitable for study participation by the investigator","ALL","85 Years",{"count":55,"type":21},150,[57],"PHASE2","The goal of this clinical trial is to learn if NRICM102 (a Traditional Chinese Medicine) works to treat community-acquired pneumonia (CAP) in adults when added to standard antibiotic therapy. It will also learn about the safety of NRICM102. The main questions it aims to answer are:\n\n1. Does NRICM102 help participants reach clinical stability faster compared to placebo?\n2. What medical problems do participants have when taking NRICM102?\n\nResearchers will compare NRICM102 to a placebo (a look-alike substance that contains no drug) to see if NRICM102 works as an add-on treatment for community-acquired pneumonia.\n\nParticipants will:\n\n1. Take NRICM102 or a placebo (2 sachets, 3 times daily) in addition to standard intravenous antibiotic treatment for 7 days\n2. Be hospitalized and visited by the study team on Day 1, Day 4, and Day 8 for vital sign monitoring, symptom assessments, laboratory tests, and chest X-ray examinations\n3. Be contacted by telephone on Day 30 to check if they were readmitted to the hospital after discharge",[60,61,62,29,63],"Mild to Moderate","Community-Acquired Pneumonia (CAP)","Antibiotic Therapy","Hospitalisation",[65,61,66],"NRICM102","National Research Institute of Chinese Medicine, Ministry of Health and Welfare","NOT_YET_RECRUITING","2026-05-07",{"date":70,"type":37},"2026-05-13",{"date":72,"type":21},"2026-06",{"date":74,"type":21},"2027-11",{"name":66,"class":76},"OTHER_GOV",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":52,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":45},"100630597","ondansetron-lozenge-versus-intravenous-for-prevention-of-shivering-in-tonsillectomy-100630597","NCT07489742","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 4 to 15 years.\n* Both sexes.\n* American Society of Anesthesiology (ASA) physical status I-II.\n* Children undergoing tonsillectomy under general anesthesia.\n\nExclusion Criteria:\n\n* Allergy to ondansetron.\n* History of sleep apnea.\n* Cardiac and respiratory diseases.\n* Upper respiratory tract infection.\n* Taking corticosteroids.","4 Years","15 Years",{"count":87,"type":21},210,[24],"This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in tonsillectomy.",[27,28,29,31,91],"Tonsillectomy","2026-03-25",{"date":94,"type":37},"2026-03-27",{"date":92,"type":37},{"date":97,"type":21},"2026-09-01",{"name":43,"class":44},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100575875","phase-4-nebulized-versus-intravenous-tranexamic-acid-on-surgical-field-quality-in-patients-undergoing-endoscopic-sinus-surgeries-100575875","NCT06777966","Nebulized Versus Intravenous Tranexamic Acid on Surgical Field Quality in Patients Undergoing Endoscopic Sinus Surgeries","Effect of Preoperative Nebulized Versus Intravenous Tranexamic Acid on Surgical Field Quality in Patients Undergoing Endoscopic Sinus Surgeries: a Randomized Controlled Comparative Study","Inclusion Criteria:\n\n* Age between 18 and 60 years.\n* American Society of Anesthesiologists (ASA) class I and II patients.\n* Endoscopic sinus surgeries under general anesthesia.\n\nExclusion Criteria:\n\n* Patient's refusal.\n* American Society of Anesthesiologists (ASA) class III or IV patients.\n* Underlying uncontrolled hypertension.\n* Known history bleeding disorder.\n* Patients on anticoagulant therapy.\n* Allergy to any of the drugs utilized in this study.\n* History of nonsteroidal anti-inflammatory drugs within 48 hours of scheduled surgery.\n* Inadvertent intra-operative vascular injury.","60 Years",{"count":108,"type":21},60,[110],"PHASE4","Intraoperative bleeding is one of the vital problems for anesthesiologists and surgeons, during endoscopic nasal surgery; where the surgical field is very limited and surrounded by vital structures. The tinniest amount of blood in such surgical field can obscure the anatomy and clog the tip of the endoscope, requiring repeated irrigations and suctioning; both of which have traumatic effects on the friable nasal mucosa. Anesthetic techniques to minimize bleeding during endoscopic nasal surgery are of primary importance for a safe and effective procedure, reducing operative time and shortening post-operative recovery.\n\nGood surgical conditions could be achieved with systemic, topical, or regional anesthetic techniques. The use of topical and regional techniques has been gaining popularity in recent years as an alternative to the administration of heavy premedication, high narcotic doses, intravenous lignocaine, clonidine, calcium channel blockers, sodium nitroprusside, beta-adrenergic blockers, and magnesium sulfate, which may produce a lack of alertness, respiratory depression, hypoxia, nausea and vomiting, and delayed recovery.\n\nRecent studies have shown that the use of tranexamic acid could be a safe and effective management option for hemostasis in a wide range of specialties. Tranexamic acid (TXA) is a synthetic lysine derivative that blocks the lysine binding site on plasminogen, thus inactivating its conversion to plasmin and hence attenuating its fibrinolysis effects. When given as a one-time operative systemic dose, it can reduce intraoperative surgical blood loss. More recently, it has been used in its nebulized or topical form to treat bleeding in anatomically sequestered areas. Its use has been described for epistaxis, cancer-related hemoptysis, and post-tonsillectomy bleeding. Though systemic doses of tranexamic acid have proven their efficiency in reducing intraoperative bleeding, other forms of administration have not been widely researched. The use of nebulized form is expected to provide a targeted route and localized effect with reduced systemic side effects. Adverse effects of systemic administration of tranexamic acid include seizures, nausea, vomiting, diarrhea, pulmonary embolism, deep vein thrombosis, anaphylaxis, and other visual disturbance.\n\nThe purpose of this study was to assess the effect of pre-emptive nebulized tranexamic acid versus intravenous tranexamic acid on endoscopic visualization and bleeding rate during endoscopic sinus surgeries.",[113,29,114,115],"Nebulization","Surgical Field","Endoscopic Sinus Surgeries","2025-01-19",{"date":118,"type":37},"2025-01-22",{"date":120,"type":37},"2025-01-18",{"date":122,"type":21},"2025-07-01",{"name":124,"class":44},"Cairo University",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":45},"100554379","phase-4-intravenous-tnk-vs-tpa-for-ais-treatment-on-msua-prospective-multicenter-rct-100554379","NCT06498323","Intravenous TNK vs TPA for AIS Treatment on MSU,a Prospective Multicenter RCT","Intravenous Tenecteplase Versus Alteplase for Acute Ischemic Stroke Treatment on Mobile Stroke Units, a Prospective Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed as Acute ischemic stroke within 4.5 hr of symptom onset\n* Age \\> 18 years old\n* No contraindication for thrombolytic drug\n* Informed consent from patients\n\nExclusion Criteria:\n\n* Diagnosed as Acute ischemic stroke with more than 4.5 hours of symptom onset or uncontained onset\n* Have contraindication for thrombolytic drugs",{"count":133,"type":21},160,[110],"Acute ischemic stroke is one of the devastating diseases that increase hospitalization, disabilities, and deaths worldwide. Current treatment with intravenous thrombolytic agent can help reduce disabilities and improve quality of life. Intravenous Alteplase is proven benefit and now used as the first-line drug for acute ischemic stroke with symptom onset less than 4.5 hours and without contraindications.\n\nTenecteplase, a genetically engineered tissue-type plasminogen activator, has been questioned to treat acute ischemic stroke instead of intravenous alteplase. Tenecteplase has more advantages over alteplase including higher fibrin specificity, longer half-life and easier to administer as a single intravenous bolus. The efficacy and safety of intravenous tenecteplase has been studied recently. In 2017, A phase 3 randomized open-label, blinded trial (NOR-TEST) 6 showed that there were no significant differences in efficacy and safety between tenecteplase and alteplase in mild stroke patients. A study in 2020, in the setting of acute large artery occlusion, Tenecteplase resulted in a better 90-day neurological outcome and provided more benefits in reperfusion before endovascular thrombectomy10. Regarding safety concerns, tenecteplase showed no significant higher incidence of intracerebral hemorrhage. Administration, tenecteplase might be better in the setting of the case on mobile stroke units. Assuming, earlier reperfusion by thrombolytic drug may have improved patient's neurologic outcomes. We aim to compare the efficacy and safety between intravenous tenecteplase and alteplase in acute ischemic stroke patients given on mobile stroke units within 4.5 hours after symptom onset.",[29,137,138],"Thrombosis","Acute Ischemic Stroke",[140,141,142],"Acute ischemic stroke","Mobile stroke unit","Intravenous Tenecteplase","2024-07-05",{"date":145,"type":37},"2024-07-12",{"date":147,"type":37},"2022-08-03",{"date":149,"type":21},"2025-08-31",{"name":151,"class":44},"Mahidol University"]